Rani Therapeutics reports Q3 2025 results, announces $1.085B Chugai collaboration and $60.3M financing

Rani Therapeutics Holdings, Inc.

Entered collaboration with Chugai for oral therapy using RaniPill platform; potential total value up to $1.085B including options for up to five additional targets.
Closed $60.3M oversubscribed private placement led by Samsara BioCapital with participation from RA Capital, Anomaly, Special Situations Funds, and Invus.
Appointed Abraham Bassan (Samsara BioCapital) and Vasudev Bailey, Ph.D. (Anomaly Ventures) to the Board of Directors.
Cash runway expected into 2028; Phase 1 trial of oral obesity therapy RT-114 planned by end of 2025.
Net loss for Q3 2025 was $7.9M, improved from $12.7M in prior year period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.